» Articles » PMID: 30995943

BRCA1 Mutations Attenuate Super-enhancer Function and Chromatin Looping in Haploinsufficient Human Breast Epithelial Cells

Overview
Specialty Oncology
Date 2019 Apr 19
PMID 30995943
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: BRCA1-associated breast cancer originates from luminal progenitor cells. BRCA1 functions in multiple biological processes, including double-strand break repair, replication stress suppression, transcriptional regulation, and chromatin reorganization. While non-malignant cells carrying cancer-predisposing BRCA1 mutations exhibit increased genomic instability, it remains unclear whether BRCA1 haploinsufficiency affects transcription and chromatin dynamics in breast epithelial cells.

Methods: H3K27ac-associated super-enhancers were compared in primary breast epithelial cells from BRCA1 mutation carriers (BRCA1) and non-carriers (BRCA1). Non-tumorigenic MCF10A breast epithelial cells with engineered BRCA1 haploinsufficiency were used to confirm the H3K27ac changes. The impact of BRCA1 mutations on enhancer function and enhancer-promoter looping was assessed in MCF10A cells.

Results: Here, we show that primary mammary epithelial cells from women with BRCA1 mutations display significant loss of H3K27ac-associated super-enhancers. These BRCA1-dependent super-enhancers are enriched with binding motifs for the GATA family. Non-tumorigenic BRCA1 MCF10A cells recapitulate the H3K27ac loss. Attenuated histone mark and enhancer activity in these BRCA1 MCF10A cells can be partially restored with wild-type BRCA1. Furthermore, chromatin conformation analysis demonstrates impaired enhancer-promoter looping in BRCA1 MCF10A cells.

Conclusions: H3K27ac-associated super-enhancer loss is a previously unappreciated functional deficiency in ostensibly normal BRCA1 mutation-carrying breast epithelium. Our findings offer new mechanistic insights into BRCA1 mutation-associated transcriptional and epigenetic abnormality in breast epithelial cells and tissue/cell lineage-specific tumorigenesis.

Citing Articles

Epigenetic drugs in cancer therapy.

Suraweera A, OByrne K, Richard D Cancer Metastasis Rev. 2025; 44(1):37.

PMID: 40011240 PMC: 11865116. DOI: 10.1007/s10555-025-10253-7.


Super-Enhancers and Their Parts: From Prediction Efforts to Pathognomonic Status.

Vasileva A, Gladkova M, Ashniev G, Osintseva E, Orlov A, Kravchuk E Int J Mol Sci. 2024; 25(6).

PMID: 38542080 PMC: 10969950. DOI: 10.3390/ijms25063103.


Genetic variant in a BaP-activated super-enhancer increases prostate cancer risk by promoting AhR-mediated expression.

Fan L, Wang H, Ben S, Cheng Y, Chen S, Ding Z J Biomed Res. 2024; 38(2):149-162.

PMID: 38410974 PMC: 11001591. DOI: 10.7555/JBR.37.20230049.


The Tumor Suppressor BRCA1/2, Cancer Susceptibility and Genome Instability in Gynecological and Mammary Cancers.

Oubaddou Y, Ben Ali F, Oubaqui F, Qmichou Z, Bakri Y, Ameziane El Hassani R Asian Pac J Cancer Prev. 2023; 24(9):3139-3153.

PMID: 37774066 PMC: 10762740. DOI: 10.31557/APJCP.2023.24.9.3139.


Chromatin Organization and Transcriptional Programming of Breast Cancer Cell Identity.

Bobbitt J, Seachrist D, Keri R Endocrinology. 2023; 164(8).

PMID: 37394919 PMC: 10370366. DOI: 10.1210/endocr/bqad100.


References
1.
Calo E, Wysocka J . Modification of enhancer chromatin: what, how, and why?. Mol Cell. 2013; 49(5):825-37. PMC: 3857148. DOI: 10.1016/j.molcel.2013.01.038. View

2.
Ma Y, Katiyar P, Jones L, Fan S, Zhang Y, Furth P . The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol. 2005; 20(1):14-34. PMC: 4031608. DOI: 10.1210/me.2004-0488. View

3.
Konishi H, Mohseni M, Tamaki A, Garay J, Croessmann S, Karnan S . Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A. 2011; 108(43):17773-8. PMC: 3203756. DOI: 10.1073/pnas.1110969108. View

4.
Eisen A, Lubinski J, Klijn J, Moller P, Lynch H, Offit K . Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005; 23(30):7491-6. DOI: 10.1200/JCO.2004.00.7138. View

5.
Kim S, Yu N, Kaang B . CTCF as a multifunctional protein in genome regulation and gene expression. Exp Mol Med. 2015; 47:e166. PMC: 4491725. DOI: 10.1038/emm.2015.33. View